Full-Time

Quality Assurance Associate Manager

Growth Marketing Operations

Updated on 9/3/2026

Hinge Health

Hinge Health

1,001-5,000 employees

Digital clinic delivering tech-enabled physical therapy

Compensation Overview

$121k - $167k/yr

+ 401(k) match + ESPP

San Francisco, CA, USA

Hybrid

Three days on-site per week required.

Bachelor's

Category
Growth & Marketing
Required Skills
Python
JavaScript
Postman
Webhooks
SQL
Quality Assurance (QA)
Salesforce
REST APIs
Looker
Excel/Numbers/Sheets

Get referred to Hinge Health

See people who can refer or advise you

Requirements
  • A bachelor's degree in Computer Science, Computer Engineering, or a related field of study is required.
  • At least 2 years of experience in quality assurance, marketing operations, or customer relationship management platform testing is required.
  • At least 2 years of hands-on experience with marketing automation platforms such as Iterable, Braze, or Salesforce Marketing Cloud is required.
  • At least 2 years of experience with email, SMS, push, and in-app messaging campaigns is required.
  • Familiarity with segmentation logic, audience targeting, and personalization strategies is required.
  • The ability to analyze campaign performance data using Google Sheets, Looker, or Mode Analytics is required.
  • Strong debugging and troubleshooting skills are required, particularly for diagnosing segmentation and campaign execution issues.
  • Experience working cross-functionally with marketing, customer relationship management, and analytics teams is required.
  • Demonstrated curiosity about artificial intelligence and automation is required, with the ability to use emerging tools thoughtfully to improve quality assurance workflows while maintaining judgment and accountability for final outputs.
Responsibilities
  • Develop and execute comprehensive test plans for marketing campaigns and audience segmentation logic.
  • Validate dynamic content, personalization rules, event triggers, and data accuracy before deployment.
  • Identify, document, and track issues related to segmentation mismatches, automation logic, and campaign execution failures.
  • Apply manual, exploratory, and repeatable validation methods based on campaign complexity, risk, and timeline.
  • Use artificial-intelligence-assisted workflows where appropriate to accelerate pre-launch checks, identify inconsistencies, and improve test coverage while maintaining human review and final quality assurance accountability.
  • Investigate live campaign issues using platform logs, segmentation reports, and campaign performance data.
  • Collaborate with marketing operations, customer relationship management, and data teams to troubleshoot campaign execution errors.
  • Validate webhook integrations, application programming interface connections, and cross-channel marketing triggers as needed.
  • Surface recurring failure patterns and recommend practical guardrails, checklists, or workflow changes that reduce repeat issues over time.
  • Ensure audience segmentation accuracy and data integrity before deployment.
  • Use SQL or marketing analytics tools to verify segmentation logic and troubleshoot discrepancies.
  • Validate tracking parameters, including UTM parameters and attribution tags, to ensure accurate campaign performance reporting.
  • Develop quality assurance checklists, testing procedures, and best practices for marketing campaign validation.
  • Document troubleshooting steps and campaign quality assurance methodologies to improve team efficiency.
  • Provide recommendations to enhance workflow efficiency, audience segmentation, and testing approaches.
  • Monitor campaign quality signals after launch and use findings to improve future test strategies and defect prevention.
  • Partner with teammates to trial more automated or artificial-intelligence-supported approaches to campaign quality assurance, anomaly detection, and data validation where they reduce manual work without compromising quality.
Desired Qualifications
  • Basic SQL skills to analyze campaign data and investigate segmentation issues.
  • Experience using Postman, Retool, or similar application programming interface testing tools for troubleshooting integrations.
  • Familiarity with quality assurance automation tools or scripting languages such as Python or JavaScript for efficiency improvements.
  • Understanding of direct mail quality assurance processes and print vendor integrations.
  • Knowledge of email deliverability best practices, sender reputation management, and campaign performance monitoring.
  • Experience in fast-paced, agile marketing environments with rapid iteration cycles.
  • Experience experimenting with artificial intelligence tools, prompt-based workflows, or automation assistants in a marketing, operations, or quality assurance context.
  • Familiarity with human-in-the-loop quality assurance approaches where artificial intelligence accelerates validation while humans remain responsible for judgment, escalation, and release readiness.

Hinge Health runs a digital clinic for joint and muscle care, delivering physical therapy through a mobile app and a clinical care team. Users follow personalized exercise programs, track progress, and communicate with their care team while learning about their condition. Revenue comes from partnerships with employers and health plans that cover the service, making it free for users. The platform blends clinician-guided care with technology to make physical therapy accessible and scalable beyond traditional clinics.

Company Size

1,001-5,000

Company Stage

IPO

Headquarters

San Francisco, California

Founded

2014

Get referred to Hinge Health

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Q2 2026 revenue hit $212.8 million, up 53% year over year.
  • August 4, 2026 guidance rose to $856-$860 million for 2026.
  • Cylinder Health adds GI care, a $135 billion market, by 2027.

What critics are saying

  • Insiders sold $285 million in 90 days, including Insight Holdings and James Pursley.
  • Cylinder's $105 million integration must close in Q3 2026 and launch by 2027.
  • If employers switch to lower-cost point solutions, Hinge Health becomes a commoditized benefits vendor.

What makes Hinge Health unique

  • AI-powered MSK clinic combines TrueMotion, Enso, and licensed clinicians for personalized therapy.
  • June 2026 Investor Day said Robin cut clinical hours 97%.
  • Hinge Health serves over 2,929 clients, including more than half Fortune 100.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Competitive compensation with meaningful equity

Medical, Dental, Vision, Disability and Life Insurance (We cover 100% of your premium and 75% for your dependents)

Flexible PTO

FSA/HSA accounts

Family & fertility benefit through Maven Clinic

401(k) match

3 months paid parental leave

Professional Development budget

Quarterly lifestyle benefit to use towards WFH equipment & fitness

Generous mental health stipend

Work from home policy

Opportunity to join a fantastically talented, diverse, and passionate team at a pivotal time in the company's lifecycle

Growth & Insights and Company News

Headcount

6 month growth

-1%

1 year growth

-1%

2 year growth

-2%
Yahoo Finance
Sep 4th, 2026
Hinge Health director sells $106K in shares, retains $2.6M stake after 50% stock surge

Kristina M. Leslie, a Director at Hinge Health, sold 1,200 shares of Class A common stock for $105,876 on 20 August 2026, according to an SEC Form 4 filing. The shares were sold at a weighted average price of $88.23. Following the transaction, Leslie retains 30,387 shares in the digital health company, representing a 0.03% ownership stake valued at approximately $2.6 million. Hinge Health's stock has delivered a 50% total return over the past year. The San Francisco-based company, founded in 2012, specialises in musculoskeletal healthcare software solutions. It has a market capitalisation of $6.6 billion and trailing twelve-month revenues of $720 million. Analysts remain largely bullish on Hinge Health, with 94% rating it a buy.

Investor's Business Daily
Aug 27th, 2026
Hinge Health soars 95% as AI pain management platform expands with $105M Cylinder Health acquisition

Hinge Health, which offers an AI-enabled app for pain management, saw shares surge 95% year-to-date and touch an all-time high on Thursday. The company reported mixed Q2 results on 4 August, with earnings of 59 cents per share on $213 million revenue, slightly missing analyst expectations on earnings but beating on sales. Client numbers grew to 2,929 from 2,359 year-over-year. Hinge Health raised its full-year sales outlook to $858 million, representing 46% growth, up from an earlier forecast of $801 million. The company is expanding beyond its core musculoskeletal platform into migraine management and surgical care. In August, it announced an all-cash acquisition of Cylinder Health for $105 million to add gastrointestinal care capabilities. Institutional investors now hold 51% of outstanding shares.

MarketBeat
Aug 26th, 2026
Hinge Health (NYSE:HNGE) hits new 1-year high - here's why.

Hinge Health (NYSE:HNGE) hits new 1-year high - here's why. August 26, 2026 Key points. * Hinge Health shares reached a new 52-week high of $93.50, trading up 3.6% with a market capitalization of approximately $7.51 billion. * The company reported strong quarterly results, including EPS of $0.59 versus the $0.28 consensus estimate and revenue of $212.82 million, up 53% year over year. * Analyst sentiment remains broadly positive, with a consensus "Moderate Buy" rating and $100.57 price target, although insiders sold approximately $285.2 million of stock over the past 90 days. * MarketBeat previews the top five stocks to own by September 1st. Hinge Health Inc. (NYSE:HNGE - Get Free Report)'s stock price hit a new 52-week high during mid-day trading on Wednesday. The company traded as high as $93.50 and last traded at $93.31, with a volume of 911642 shares changing hands. The stock had previously closed at $89.87. Analyst upgrades and downgrades. Several research firms recently issued reports on HNGE. Raymond James Financial boosted their target price on shares of Hinge Health from $70.00 to $80.00 and gave the company an "outperform" rating in a research note on Monday, June 15th. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Hinge Health in a report on Monday, August 3rd. Barclays increased their target price on shares of Hinge Health from $97.00 to $100.00 and gave the stock an "overweight" rating in a research note on Wednesday, August 5th. Wall Street Zen lowered Hinge Health from a "buy" rating to a "hold" rating in a research note on Saturday, August 8th. Finally, Citizens Jmp raised their price objective on Hinge Health from $96.00 to $107.00 and gave the company a "market outperform" rating in a report on Wednesday, August 5th. One equities research analyst has rated the stock with a Strong Buy rating, fourteen have given a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and a consensus price target of $100.57. Hinge Health trading up 3.6%. The stock's fifty day simple moving average is $82.25 and its 200-day simple moving average is $59.24. The company has a market capitalization of $7.51 billion, a price-to-earnings ratio of 72.73 and a beta of 1.30. Hinge Health (NYSE:HNGE - Get Free Report) last released its earnings results on Tuesday, August 4th. The company reported $0.59 EPS for the quarter, topping the consensus estimate of $0.28 by $0.31. The firm had revenue of $212.82 million during the quarter. Hinge Health had a return on equity of 51.60% and a net margin of 15.15%.The company's revenue for the quarter was up 53.0% compared to the same quarter last year. During the same period in the previous year, the firm earned $0.59 earnings per share. On average, analysts anticipate that Hinge Health Inc. will post 1.25 EPS for the current fiscal year. Insider activity. In related news, major shareholder Insight Holdings Group, Llc sold 181,499 shares of the business's stock in a transaction on Thursday, July 9th. The shares were sold at an average price of $90.20, for a total transaction of $16,371,209.80. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, President James Pursley sold 33,000 shares of the stock in a transaction on Friday, August 21st. The shares were sold at an average price of $88.05, for a total value of $2,905,650.00. Following the completion of the transaction, the president directly owned 706,235 shares in the company, valued at $62,183,991.75. This trade represents a 4.46% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 3,643,373 shares of company stock valued at $285,194,378 in the last 90 days. Company insiders own 18.92% of the company's stock. Hedge funds weigh in on Hinge Health. Hedge funds have recently added to or reduced their stakes in the stock. BNP Paribas Financial Markets raised its stake in shares of Hinge Health by 162.7% during the 4th quarter. BNP Paribas Financial Markets now owns 727,672 shares of the company's stock worth $33,800,000 after buying an additional 450,643 shares in the last quarter. UBS Group AG boosted its position in shares of Hinge Health by 168.8% during the 4th quarter. UBS Group AG now owns 356,701 shares of the company's stock worth $16,569,000 after purchasing an additional 223,980 shares in the last quarter. Royce & Associates LP acquired a new position in shares of Hinge Health during the 4th quarter worth $2,091,000. Alkeon Capital Management LLC lifted its stake in shares of Hinge Health by 110.4% in the fourth quarter. Alkeon Capital Management LLC now owns 791,104 shares of the company's stock valued at $36,747,000 after purchasing an additional 415,093 shares during the period. Finally, Zurcher Kantonalbank Zurich Cantonalbank lifted its stake in shares of Hinge Health by 755.1% in the fourth quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 27,354 shares of the company's stock valued at $1,271,000 after purchasing an additional 24,155 shares during the period. Hinge Health company profile. Hinge Health NYSE: HNGE is a digital musculoskeletal (MSK) clinic that provides end-to-end solutions for the prevention and management of musculoskeletal conditions. The company's platform combines wearable motion sensors, personalized exercise therapy guided by licensed physical therapists, and behavioral health coaching to deliver tailored treatment plans. By integrating technology with evidence-based clinical protocols, Hinge Health aims to reduce pain, improve mobility and decrease reliance on more invasive interventions such as surgery or opioid prescriptions. Founded in 2015 and headquartered in San Francisco, Hinge Health partners with employers, health plans and other payers to offer its self-directed, app-based programs. This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to [email protected]. Continue following MarketBeat Before you consider Hinge Health, you'll want to hear this. MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Hinge Health wasn't on the list. While Hinge Health currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys. Tesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you'll find 7 stocks that could play a major role in the next tech-driven market boom.

Yahoo Finance
Aug 5th, 2026
Hinge Health reports Q2 earnings of $0.59 per share, revenues surpass estimates at $213M

Hinge Health reported second quarter earnings of $0.59 per share, meeting analyst expectations. Revenue reached $212.82 million, exceeding estimates by 6.14%. This compares to revenues of $139.1 million in the same quarter last year. The company has surpassed consensus revenue estimates in each of the last four quarters. Over the past four quarters, it has beaten earnings per share estimates three times. Shares have gained 67.2% since the beginning of the year, significantly outpacing the S&P 500's 11% gain. The company currently holds a Zacks Rank #1 (Strong Buy) rating, suggesting continued outperformance. For the upcoming quarter, analysts expect earnings of $0.67 per share on revenues of $209.63 million.

MarketBeat
Aug 5th, 2026
Wells Fargo & Company forecasts strong price appreciation for Hinge Health (NYSE:HNGE) stock.

Wells Fargo & Company forecasts strong price appreciation for Hinge Health (NYSE:HNGE) stock. August 5, 2026 Key points. * Wells Fargo raised its Hinge Health price target from $90 to $103 and maintained an "overweight" rating, implying 16.7% upside from the prior close. Analysts' consensus rating is "Moderate Buy," with an average target of $96.33. * Hinge Health reported quarterly revenue of $212.82 million, up 53% year over year, and earnings of $0.59 per share versus the $0.28 consensus estimate. Management also issued third-quarter revenue guidance of $223 million to $225 million, above analysts' expectations. * Despite strong growth, profitability remains a concern, with a negative net margin and return on equity; insiders have also sold approximately $290.7 million of shares over the past three months. * Five stocks to consider instead of Hinge Health. Hinge Health (NYSE:HNGE - Get Free Report) had its price target upped by research analysts at Wells Fargo & Company from $90.00 to $103.00 in a report released on Wednesday,Benzinga reports. The firm currently has an "overweight" rating on the stock. Wells Fargo & Company's price objective points to a potential upside of 16.70% from the company's previous close. Several other equities research analysts have also commented on HNGE. Truist Financial boosted their target price on shares of Hinge Health from $79.00 to $85.00 and gave the stock a "buy" rating in a research report on Thursday, June 11th. Robert W. Baird raised their price objective on shares of Hinge Health from $55.00 to $65.00 and gave the company a "neutral" rating in a research note on Wednesday, June 17th. Barclays upped their target price on shares of Hinge Health from $97.00 to $100.00 and gave the stock an "overweight" rating in a research report on Wednesday. Evercore reaffirmed an "outperform" rating and issued a $105.00 target price on shares of Hinge Health in a report on Wednesday. Finally, Morgan Stanley lifted their price target on shares of Hinge Health from $72.00 to $108.00 and gave the company an "overweight" rating in a research report on Monday, July 13th. Two investment analysts have rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating, one has given a Hold rating and one has given a Sell rating to the company's stock. Based on data from MarketBeat.com, Hinge Health has an average rating of "Moderate Buy" and a consensus target price of $96.33. Hinge Health stock performance. NYSE:HNGE traded up $8.84 during mid-day trading on Wednesday, reaching $88.26. The stock had a trading volume of 1,849,223 shares, compared to its average volume of 1,506,248. Hinge Health has a twelve month low of $30.08 and a twelve month high of $91.50. The business has a 50 day simple moving average of $74.52 and a 200 day simple moving average of $54.18. The firm has a market capitalization of $6.83 billion, a price-to-earnings ratio of -7.15 and a beta of 1.30. Discover more Stock Market News Business News Hinge Health (NYSE:HNGE - Get Free Report) last posted its quarterly earnings results on Tuesday, August 4th. The company reported $0.59 earnings per share for the quarter, beating analysts' consensus estimates of $0.28 by $0.31. The firm had revenue of $212.82 million for the quarter. Hinge Health had a negative return on equity of 310.62% and a negative net margin of 78.95%.The firm's quarterly revenue was up 53.0% compared to the same quarter last year. During the same quarter last year, the firm earned $0.59 earnings per share. As a group, sell-side analysts expect that Hinge Health will post 1.37 earnings per share for the current year. Insider buying and selling at Hinge Health. In other news, Chairman Gabriel M.I. Mecklenburg sold 83,334 shares of the business's stock in a transaction on Monday, June 1st. The stock was sold at an average price of $60.22, for a total value of $5,018,373.48. Following the completion of the transaction, the chairman directly owned 83,334 shares of the company's stock, valued at $5,018,373.48. The trade was a 50.00% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, major shareholder Insight Holdings Group, Llc sold 1,466,667 shares of the stock in a transaction on Monday, June 29th. The shares were sold at an average price of $82.83, for a total value of $121,484,027.61. The SEC filing for this sale provides additional information. Insiders have sold 3,766,556 shares of company stock valued at $290,713,052 in the last three months. 18.92% of the stock is currently owned by company insiders. Institutional inflows and outflows. Institutional investors have recently bought and sold shares of the business. Vista Investment Partners LLC purchased a new position in shares of Hinge Health during the 2nd quarter worth $3,468,000. Assenagon Asset Management S.A. purchased a new stake in shares of Hinge Health in the second quarter valued at $6,867,000. California State Teachers Retirement System grew its position in shares of Hinge Health by 35.2% in the first quarter. California State Teachers Retirement System now owns 19,141 shares of the company's stock valued at $738,000 after purchasing an additional 4,986 shares during the period. Estuary Capital Management LP acquired a new position in Hinge Health in the first quarter valued at $15,201,000. Finally, Lazard Asset Management LLC increased its stake in Hinge Health by 0.6% in the first quarter. Lazard Asset Management LLC now owns 63,705 shares of the company's stock valued at $2,456,000 after purchasing an additional 386 shares during the last quarter. Key stories impacting Hinge Health. Here are the key news stories impacting Hinge Health this week: * Positive Sentiment: Strong second-quarter performance: Hinge Health reported $212.8 million in revenue, up 53% year over year, and earnings of $0.59 per share. That exceeded the $0.28 consensus estimate cited by MarketBeat, although Zacks characterized the result as in line with its own consensus. The company also said free cash flow more than tripled from the prior year. Hinge Health reports record second-quarter 2026 financial results * Positive Sentiment: Above-consensus third-quarter outlook: Management forecast third-quarter revenue of $223 million to $225 million, well above the roughly $211 million analyst consensus. The guidance reinforces expectations for continued strong growth. Hinge Health earnings conference call * Positive Sentiment: Analyst target raised: Needham increased its price target from $76 to $97 and assigned a "Buy" rating, implying substantial upside from recent trading levels. Benzinga analyst update * Positive Sentiment: Expansion into gastrointestinal care: Hinge Health agreed to acquire Cylinder Health for $105 million in cash. The deal is intended to add a virtual-first GI Care Program to its existing musculoskeletal and migraine offerings, expanding its addressable market. Hinge Health to acquire Cylinder Health * Neutral Sentiment: CEO Daniel Perez's earnings interview and the Q2 earnings call provide additional detail on the company's operating performance, strategy and outlook. Daniel Perez Hinge Health CEO interview * Negative Sentiment: Profitability remains a risk: Despite the quarterly EPS beat, Hinge Health continues to report a negative net margin and negative return on equity. The $105 million all-cash acquisition also creates execution and integration risks. About Hinge Health. Hinge Health NYSE: HNGE is a digital musculoskeletal (MSK) clinic that provides end-to-end solutions for the prevention and management of musculoskeletal conditions. The company's platform combines wearable motion sensors, personalized exercise therapy guided by licensed physical therapists, and behavioral health coaching to deliver tailored treatment plans. By integrating technology with evidence-based clinical protocols, Hinge Health aims to reduce pain, improve mobility and decrease reliance on more invasive interventions such as surgery or opioid prescriptions. Founded in 2015 and headquartered in San Francisco, Hinge Health partners with employers, health plans and other payers to offer its self-directed, app-based programs. This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to [email protected]. Continue following MarketBeat Before you consider Hinge Health, you'll want to hear this. MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Hinge Health wasn't on the list. While Hinge Health currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys. Enter your email address and we'll send you MarketBeat's list of ten stocks set to soar in Summer 2026, despite the threat of tariffs and what's happening in Iran. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.